Cookie use on MRCVSonline
We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive all cookies.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

‘Trojan horse’ antibiotic shows promise
"Our results support cefiderocol as a novel approach that might be used to overcome Gram-negative resistance." (Stock photo)
Drug works by tricking bacteria in allowing it to enter 

A new antibiotic that acts like the Trojan horse in Greek legend has shown promise in phase two trials, scientists have said.

Cefiderocol works by tricking bacteria in allowing it to enter. It was found to be as effective as the current standard-of-care antibiotic, in the treatment of complicated urinary tract infections (UTIs) caused by several multi-drug-resistant Gram-negative bacteria.

Findings published in The Lancet Infectious Diseases journal suggest that patients treated with cefiderocol had a higher and more sustained level of pathogen eradication; and similar clinical outcomes to those treated with imipenem-cilastatin.

The study randomised 448 adults who had been hospitalised with a complicated UTI or uncomplicated pyelonephritis. Three hundred patients received three daily infusions of cefiderocol for seven to 10 days, while the remainder were given imipenem-cilastatin.

Seven days after treatment stopped, cefiderocol showed efficacy rates of 73 per cent and 55 per cent respectively for clinical and microbiological responses.

Lead author Dr Simon Portsmouth, from Shionogi Inc, said: "Cefiderocol was found to be both safe and tolerable in a population of older patients who were very ill with complex comorbid conditions and a wide range of multidrug-resistant pathogens. Our results support cefiderocol as a novel approach that might be used to overcome Gram-negative resistance.

"Ongoing clinical trials of pneumonia, including hospital-acquired pneumonia and ventilator-associated pneumonia, and a study in patients with carbapenem-resistant infections, will provide additional important information about cefiderocol."

Become a member or log in to add this story to your CPD history

Nominations for 2019 RSPCA Honours Awards now open

News Story 1
 People across the UK are being urged to nominate a standout animal champion for the 2019 RSPCA Honours Awards.

The awards recognise those who have worked tirelessly to improve animal welfare, campaigned on behalf of animals, or shown true bravery. Previous winners include comedian John Bishop, who was awarded Celebrity Animal Champion of the Year, and 11-year-old Lobby Cantwell, who raised more than £1,000 for the charity through mountain climbs and bike rides.

To submit a nomination or find out more about the awards visit the RSPCA website. Nominations will remain open until 4 pm on Friday, March 15.  

Click here for more...
News Shorts
New £1m project to investigate dairy cow lameness

Scotland’s Rural College (SRUC) is leading a new £1 million research project to investigate the causes of lameness in dairy cows.

One in three dairy cows are affected by lameness every day in the UK, costing the industry an estimated £250 milion annually.

The project will take three years to complete and is due to finish by November 2021.

Professor Georgios Banos of SRUC commented: “In addition to pain and discomfort to the animal, lameness is associated with decreased milk production and inflated farm costs.

“Among cows raised in the same environment, some become lame while others do not. Understanding the reasons behind this will help us develop targeted preventive practices contributing to enhanced animal welfare and farm profitability.”